ArticleDiscover oncology2026
Prognostic value of inflammation-immunity-nutrition score in patients with cancers.
Article in Discover oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe inflammation-immune-nutrition score (IINS) plays a significant role in predicting survival outcomes across various cancers. The study aimed to comprehensively evaluate the prognostic value of IINS in different cancers through a meta-analysis.
methodsA systematic literature search was conducted in PubMed, Embase, Web of Science and Scopus databases for eligible studies published up to March 15, 2026. Pooled hazard ratios (HRs) with 95% confidence intervals (CIs) were calculated to assess the associations with overall survival (OS), disease-free survival (DFS), progression-free survival (PFS) and recurrence-free survival (RFS).
resultsA total of 10 studies from 8 articles encompassing 3979 patients were included in the analysis. Pooled analysis revealed that high IINS was significantly associated with poor OS (HR:2.54, 95% CI:1.84-3.50), PFS (HR:1.87,95% CI:1.06-3.31), DFS (HR:2.30,95% CI: 1.84-2.89) and RFS (HR:3.50,95% CI: 2.06-5.93). Subgroup analysis further demonstrated the strong prognostic value of high IINS for hepatocellular carcinoma and endometrial cancer.
conclusionsThe IINS could serve as an effective prognostic indicator for patients with cancers.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.